Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive License agreement with CSPC Megalith Biopharmaceutical Co., Ltd, ...

This makes ROR-1 an attractive therapeutic target for anti-cancer drug development. RB-164 employs a novel Fc-silenced monoclonal antibody targeting ROR-1, site specific conjugation to deliver a ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

pneumonitis 1 week after completing craniospinal irradiation, ADC infusions resumed; two weeks later, the patient was admitted for pneumonia Possible ADC: Antibody-drug conjugate; RT: Radiotherapy.

Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

Myris Therapeutics™ emerged from stealth today to announce its strategic focus. Myris, formerly known as BioHybrid Solutions, ...

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...